⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413011 | 0.77 | — | — | |
| SCHEMBL29486472 | 0.77 | — | — | |
| Hydrazine SCHEMBL28805025 | 0.76 | CYP2A6 (0.35) | — | |
| SCHEMBL30374657 | 0.75 | — | — | |
| SCHEMBL29593111 | 0.75 | — | — | |
| SCHEMBL29479544 | 0.75 | — | — | |
| SCHEMBL30319394 | 0.75 | — | — | |
| SCHEMBL2232005 | 0.75 | — | — | |
| SCHEMBL2762630 | 0.75 | — | — | |
| SCHEMBL1056076 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | claimed |
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-12-16 | — | — | US | claimed |
| US-20210179602-A1 | A 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-06-17 | — | — | US | claimed |
| CN-112955447-A | Heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2021-06-11 | — | — | CN | claimed |
| EP-3781206-A2 | A 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-02-24 | — | — | EP | claimed |
| WO-2019202160-A2 | A 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2019-10-24 | — | — | WO | claimed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-3643713-B1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-07-30 | — | — | EP | disclosed |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-12-24 | — | — | US | disclosed |
| US-12139480-B2 | 5-thiazolecarboxamide kinase inhibitor and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-11-12 | — | — | US | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| WO-2000043364-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM ACETONE AND ETHYL CYANOACETATE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0076017-B1 | PHENYL SUBSTITUTED PYRIDO(1,4)BENZODIAZEPINES AND INTERMEDIATES THEREFOR | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-16 | — | — | EP | disclosed |
| US-4668675-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-05-26 | — | — | US | disclosed |
| US-4556667-A | (2-((AMINOPYRIDINYL)AMINO)PHENYL)ARYLMETHANONE INTERMEDIATES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-03 | — | — | US | disclosed |
| US-4495183-A | ANTIULCER AGENTS- GASTROLINTESTINAL DISORDERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-22 | — | — | US | disclosed |
| US-4447361-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0076017-A2 | Phenyl substituted pyrido(1,4)benzodiazepines and intermediates therefor | A.H. ROBINS COMPANY, INCORPORATED (US) | 1983-04-06 | — | — | EP | disclosed |